Evidence map›Paper›PMID 38055287›Full record

SynthesisCancer2024

Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.

Xiaoyu Zhao, Meiqi Yang, Jingyi Fan, Mei Wang, Yifan Wang, Na Qin, Meng Zhu, Yue Jiang, Olga Y Gorlova, Ivan P Gorlov and 38 more

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. A trans-omics gene-smoking interaction study of lung cancer based on consortium data.American journal of respiratory and critical care medicine · 2026
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

48 authors at 20 institutions in 13 countries.

Xiaoyu ZhaoDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Meiqi YangDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Jingyi FanDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Mei WangDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Yifan WangDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Na QinDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0001-6878-9464
Meng ZhuDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Yue JiangDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Olga Y GorlovaDepartment of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
Ivan P GorlovDepartment of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Stephen LamDepartment of Integrative Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Adonina TardónDepartment of Public Health IUOPA, University of Oviedo, ISPA and CIBERESP, Oviedo, Spain.
Chu ChenProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Gary E GoodmanPublic Health Sciences Division, Swedish Cancer Institute, Seattle, Washington, USA.
Stig E BojesenDepartment of Clinical Biochemistry, Copenhagen University Hospital, Copenhagen, Denmark.
Maria Teresa LandiNational Cancer Institute, Bethesda, Maryland, USA.
Mattias JohanssonGenetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
Angela RischDepartment of Biosciences, Allergy-Cancer-BioNano Research Centre, University of Salzburg, Salzburg, Austria.
H-Erich WichmannInstitute of Epidemiology, Helmholtz Center Munich, Neuherberg, Germany.
Heike BickeböllerDepartment of Genetic Epidemiology, University Medical Center Goettingen, Goettingen, Germany.
David C ChristianiDepartments of Environmental Health and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Gad RennertTechnion Faculty of Medicine, Carmel Medical Center, Haifa, Israel.
Susanne M ArnoldMarkey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Paul BrennanGenetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
John K FieldMolecular and Clinical Cancer Medicine, Roy Castle Lung Cancer Research Programme, The University of Liverpool Institute of Translational Medicine, Liverpool, UK.
Sanjay SheteDepartment of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7622-376X
Loïc Le MarchandEpidemiology Program, University of Hawai'i Cancer Center, Honolulu, Hawaii, USA.
Geoffrey LiuPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Rayjean J HungProsseman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Angeline S AndrewDepartment of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Lambertus A KiemeneyDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
Shanbeh ZienolddinyNational Institute of Occupational Health (STAMI), Oslo, Norway.
Kjell GrankvistDepartment of Medical Biosciences, Umeå University, Umea, Sweden.ORCID 0000-0003-4289-2097
Mikael JohanssonDepartment of Radiation Sciences, Umeå University, Umea, Sweden.
Neil E CaporasoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Penella J WollAcademic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK.
Philip LazarusDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
Matthew B SchabathDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.ORCID 0000-0003-3241-3216
Melinda C AldrichDepartment of Medicine (Division of Genetic Medicine), Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Alpa V PatelBehavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia, USA.ORCID 0000-0001-9997-1218
Michael P A DaviesInstitute of Translational Medicine, University of Liverpool, Liverpool, UK.ORCID 0000-0002-7609-4977
Hongxia MaDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-2462-9693
Guangfu JinDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0003-0249-5337
Zhibin HuDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Christopher I AmosBaylor College of Medicine, Institute for Clinical and Translational Research, Houston, Texas, USA.
Hongbing ShenDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Juncheng DaiDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-3909-5671
Jiangsu Cancer Hospital · CNCentre international de recherche sur le cancer · FRNanjing Medical University · CNNational Cancer Institute · USDartmouth College · USUniversity of Liverpool · GBAmerican Cancer Society · USBaylor College of Medicine · USBC Cancer Agency · CACarmel Medical Center · ILDartmouth–Hitchcock Medical Center · USFred Hutch Cancer Center · USGerman Cancer Research Center · DEHelmholtz Zentrum München · DEJiangsu Province Hospital · CNLunenfeld-Tanenbaum Research Institute · CAMassachusetts Department of Public Health · USMoffitt Cancer Center · USNational Institute of Occupational Health · NONephrologisches Zentrum Goettingen · DE

Funding

Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Intramural NIH HHS Z99 CA999999NCI NIH HHS R35 CA197449World Health Organization 001
6 · The paper itself

Abstract

backgroundAlthough the associations between genetic variations and lung cancer risk have been explored, the epigenetic consequences of DNA methylation in lung cancer development are largely unknown. Here, the genetically predicted DNA methylation markers associated with non-small cell lung cancer (NSCLC) risk by a two-stage case-control design were investigated.

methodsThe genetic prediction models for methylation levels based on genetic and methylation data of 1595 subjects from the Framingham Heart Study were established. The prediction models were applied to a fixed-effect meta-analysis of screening data sets with 27,120 NSCLC cases and 27,355 controls to identify the methylation markers, which were then replicated in independent data sets with 7844 lung cancer cases and 421,224 controls. Also performed was a multi-omics functional annotation for the identified CpGs by integrating genomics, epigenomics, and transcriptomics and investigation of the potential regulation pathways.

resultsOf the 29,894 CpG sites passing the quality control, 39 CpGs associated with NSCLC risk (Bonferroni-corrected p ≤ 1.67 × 10

conclusionsSixteen promising DNA methylation markers associated with NSCLC were identified. Changes of the methylation level at these CpGs might influence the development of NSCLC by regulating the expression of genes nearby. PLAIN LANGUAGE SUMMARY: The epigenetic consequences of DNA methylation in lung cancer development are still largely unknown. This study used summary data of large-scale genome-wide association studies to investigate the associations between genetically predicted levels of methylation biomarkers and non-small cell lung cancer risk at the first time. This study looked at how well larotrectinib worked in adult patients with sarcomas caused by TRK fusion proteins. These findings will provide a unique insight into the epigenetic susceptibility mechanisms of lung cancer.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdultBiomarkersCpG IslandsDNA MethylationEpigenesis, GeneticGenome-Wide Association StudyHumansBiomarkersassociation studyDNA methylationgene expressiongenetic predictionnon-small cell lung cancer risk

Identifiers

PMID38055287
PMCPMC11327897
OpenAlexW4389397708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.